Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07205718 · ClinicalTrials.gov registry record · Phase 1

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

A Phase 1 study of Advanced or Metastatic Solid Tumors, sponsored by Takeda.

Recruiting
Registry status
Phase 1
Development phase
223
Enrollment target
15
Study locations

NCT07205718 is a Phase 1 study of Advanced or Metastatic Solid Tumors that is actively recruiting participants, run by Takeda. The registered enrollment target is 223 participants, roughly in line with the 225-participant average among 19 other Advanced or Metastatic Solid Tumors trials with a reported enrollment target. The trial reports 15 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07205718, a Phase 1 study of Advanced or Metastatic Solid Tumors, is actively recruiting participants, sponsored by Takeda.

RECRUITING
Registry status
Phase 1
Development phase
223 participants
Enrollment target
15
Study locations

Study Summary

TAK-188 is a new medicine that targets a protein called CCR8, which is found on the surface of certain cells (Tregs) inside tumors. These cells can weaken the body's ability to fight cancer. TAK-188 may help to remove these Tregs. Removing these Tregs may allow more cancer-fighting cells (CD8+ T cells) to attack the tumor and potentially stop tumors from growing. In this study, researchers want to learn if TAK-188 can help the body's immune system better fight cancer in adults with advanced cancers which have not gotten better with regular treatments. The main aims of this study are to check if TAK-188 is safe in adults with advanced or spreading (metastatic) solid tumors, if participants tolerate the treatment with TAK-188 and to learn if TAK-188 works well in adults with certain advanced cancers after their previous treatments didn't work. Participants may receive TAK-188 for up to 1 year. Their health will be monitored after the treatment has ended for up to another year.

Conditions Studied

Advanced or Metastatic Solid Tumors

Interventions

  • DRUG TAK-188

Study Locations (15)

Texas

  • MD Anderson Cancer Center - Houston
  • NEXT Dallas - Irving
  • START San Antonio - San Antonio

Michigan

  • Barbara Ann Karmanos Cancer Institute - Detroit
  • START Midwest - Grand Rapids

California

  • UCLA Health-Santa Monica Cancer Care (Cancer Care - Santa Monica) - Santa Monica

Connecticut

  • Yale School of Medicine - Smilow Cancer Hospital - Center for Thoracic Cancers - New Haven

Florida

  • Florida Cancer Specialists - Lake Nona - Orlando

Maryland

  • Johns Hopkins - Baltimore

Missouri

  • Washington University - St Louis

Ohio

  • Case Comprehensive Cancer Center - Cleveland

Trial Details

FieldValue
Enrollment Target 223 participants
Start Date 2025-11-19
Est. Completion 2029-12-21
Phase Phase 1

Sponsor

Takeda

408 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07205718

The ClinicalTrials.gov registry entry for NCT07205718 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 223 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 225-participant average among 19 other Advanced or Metastatic Solid Tumors trials with a reported enrollment target. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced or Metastatic Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which TAK-188 is the first listed.

NCT07205718 reports 15 study locations spanning 12 distinct geographic areas - top geographies include Texas, Michigan, California.

Frequently Asked Questions

What is clinical trial NCT07205718 about?

NCT07205718 is a clinical study titled "A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors". TAK-188 is a new medicine that targets a protein called CCR8, which is found on the surface of certain cells (Tregs) inside tumors. These cells can weaken the body's ability to fight cancer. TAK-188 may help to remove these Tregs. Removing these Tregs may allow more cancer-fighting cells (CD8+ T cel...

What is the current status of trial NCT07205718?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 223 participants. The study started on 2025-11-19. Estimated completion is 2029-12-21.

What conditions does trial NCT07205718 study?

This clinical trial studies the following conditions: Advanced or Metastatic Solid Tumors.

What interventions are being tested in trial NCT07205718?

The interventions under investigation include: TAK-188 (DRUG).

Who is sponsoring clinical trial NCT07205718?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07205718 being conducted?

This trial has 15 study locations across California, Connecticut, Florida, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced or Metastatic Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced or Metastatic Solid Tumors

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.